|
2025
|
Invention
|
Advantageous anti-hcv combination therapy.
A synergistic pharmaceutical combination of Compound ... |
|
|
G/S
|
Pharmaceutical preparations, namely, antivirals |
|
|
G/S
|
Pharmaceutical preparations, namely, anti-virals, expressly excluding pharmaceutical preparations... |
|
|
G/S
|
Pharmaceutical preparations, namely, anti-virals, expressly excluding analgesics, nutritional sup... |
|
|
G/S
|
Pharmaceutical preparations, namely, anti-virals, expressly excluding therapeutic pharmaceuticals... |
|
2024
|
G/S
|
Pharmaceutical preparations, namely, anti-virals |
|
|
Invention
|
Dosage regimens for treatment of dengue infection.
The present invention provides advantageous h... |
|
|
Invention
|
Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-2-modified-n6- substituted purine nucleotid... |
|
|
Invention
|
Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus.
A hemi-sulfate salt of the ... |
|
|
Invention
|
2'-chloro-2'-fluoro-n2-amino-n6-methylamino purine nucleotides for flavivirus treatment.
The pre... |
|
2023
|
Invention
|
Highly active compounds against covid-19.
The present invention is the use of purine nucleotide ... |
|
|
Invention
|
Advantageous morphic form of at-527 hemi-sulfate salt.
Advantageous isolated morphic Form III of... |
|
|
Invention
|
Highly active compounds against covid-19. The present invention is the use of a small group of pu... |
|
|
Invention
|
Dosage regimens for treatment of dengue infection. The present invention provides advantageous hi... |
|
|
Invention
|
Niran interfering drugs for sars-cov-2 mutant therapy.
Methods of treatment and prevention and a... |
|
|
Invention
|
Stereoselective manufacture of selected purine phosphoramidates.
The present invention provides ... |
|
|
Invention
|
Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus. A hemi-sulfate salt of the s... |
|
|
Invention
|
Β-d-2′-deoxy-2′-α-fluoro-2′-β-c-substituted-2-modified-n6-substituted purine nucleotides for hcv ... |
|
2022
|
Invention
|
Stereoselective process of manufacture of purine phosphoramidates.
The present invention provide... |
|
|
Invention
|
6-methylamino purine nucleotides for flavivirus treatment. The present invention is directed to n... |
|
|
Invention
|
Advantageous anti-hcv combination therapy. A synergistic pharmaceutical combination of Compound 1... |
|
|
Invention
|
Advantageous morphic form of at-527 hemi-sulfate salt. Advantageous isolated morphic Form III of ... |
|
2021
|
Invention
|
Niran interfering drugs for sars-cov-2 mutant therapy. Methods of treatment and prevention and as... |
|
|
Invention
|
6-substituted purine nucleotides for rna virus treatment. The use of described compounds or pharm... |
|
|
G/S
|
Préparations pharmaceutiques, nommément, antiviraux; antiviraux oraux utilisés pour traiter les p... |
|
|
G/S
|
Pharmaceutical preparations. |
|
|
G/S
|
Scientific research in the field of pharmaceuticals and development of pharmaceutical preparation... |
|
|
Invention
|
Stereoselective manufacture of selected purine phosphoramidates. The present invention provides s... |
|
|
Invention
|
Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-2-modified-n6-substituted purine nucleotide... |
|
|
G/S
|
Préparations pharmaceutiques utilisées pour traiter ou prévenir le COVID-19, les maladies à coron... |
|
|
Invention
|
Stereoselective process of manufacture of purine phosphoramidates. The present invention provides... |
|
|
Invention
|
Highly active compounds against covid-19. The present invention is the use of purine nucleotide p... |
|
2020
|
Invention
|
Treatment of hcv infected patients with cirrhosis. A pharmaceutical composition that includes a c... |
|
|
Invention
|
6-substituted purine nucleotides for hcv treatment. A compound of the structure:
or a pharmaceu... |
|
|
Invention
|
2'-substituted-n6-substituted purine nucleotides for rna virus treatment.
The use of described c... |
|
2019
|
Invention
|
Highly active drug combination for treatment of hepatitis c virus.
A combination is provided of ... |
|
|
Invention
|
Highly active drug combination for treatment of hepatitis c virus. A combination is provided of C... |
|
|
Invention
|
2′-substituted-n6-substituted purine nucleotides for rna virus treatment. The use of described co... |
|
2018
|
Invention
|
Beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-c-substituted-2-modified-n6-substituted purine nucleotide... |
|
2017
|
Invention
|
2'-substituted-n6-substituted purine nucleotides for rna virus treatment. The use of described co... |
|
|
Invention
|
Beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-c-substituted-4′fluoro-n6-substituted-6-amino-2-substitut... |
